Along with the results of IHC in ccRCC tissues and the expression of PPARα in the 786-O cell line, our findings imply that the combination of hydroxychloroquine and GW6471 may be beneficial in treating highly differentiated ccRCC, with minimal side effects on normal renal tissues. The gene discussed is PPARA; the disease is nonpapillary renal cell carcinoma.